Share on LinkedInShare on LinkedIn

ARTICLE · 30 JANUARY 2017

FDA Issues Draft Guidance On Biosimilar Interchangeability

Ropes & Gray LLP
Ropes & Gray LLP
Contributor
Ropes & Gray LLP

Ropes & Gray LLP

Ropes & Gray is one of the world’s most respected law firms, with offices in key business and...

View firm profile
Explore more from Ropes & Gray LLP

On January 17, 2017, the Food and Drug Administration (FDA) issued draft guidance on "Considerations in Demonstrating Interchangeability With a Reference Product."

United StatesFood, Drugs, Healthcare, Life Sciences

Introduction

On January 17, 2017, the Food and Drug Administration (FDA) issued draft guidance on "Considerations in Demonstrating Interchangeability With a Reference Product." The draft guidance sheds light on the agency's expectations for demonstrating interchangeability of biosimilar therapeutic protein products under the Public Health Service Act (PHS Act).1 In 2009, the Patient Protection and Affordable Care Act amended the PHS Act to establish an abbreviated licensure pathway for biological products shown to be biosimilar or interchangeable with an FDA-licensed biological reference product. Although FDA has issued a number of guidance documents on approval requirements for biosimilars, the draft guidance marks the first time that FDA has addressed the standards for demonstrating interchangeability.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from